Ian Kalvinskas Pediatric Liver Cancer Early Detection and Screening Act

Download PDF

Bill ID: 119/hr/5355

Last Updated: July 16, 2026

Ian Kalvinskas Pediatric Liver Cancer Early Detection and Screening Act

HR. 5355, 119th Congress — read as touching Hospitals & Health Systems.

The sponsor

Rep. Costa, Jim [D-CA-21]

Every bill has someone who introduced it. That name is where the paper trail starts.

The money

$94,000 raised

28 itemised contributions to this sponsor, pulled from FEC filings.

The alignment

55% match to Project 2025

This bill's text tracks the "Department of Health and Human Services" section, p. 533-535 of the Mandate for Leadership.

Bill's Journey to Becoming a Law

Track this bill's progress through the legislative process

Latest Action

Sponsor introductory remarks on measure. (CR H4418)

September 17, 2025

Introduced

📍 Current Status

Next: The bill will be reviewed by relevant committees who will debate, amend, and vote on it.

🏛️

Committee Review

🗳️

Floor Action

✅

Passed House

🏛️

Senate Review

🎉

Passed Congress

🖊️

Presidential Action

⚖️

Became Law

📚 How does a bill become a law?

1. Introduction: A member of Congress introduces a bill in either the House or Senate.

2. Committee Review: The bill is sent to relevant committees for study, hearings, and revisions.

3. Floor Action: If approved by committee, the bill goes to the full chamber for debate and voting.

4. Other Chamber: If passed, the bill moves to the other chamber (House or Senate) for the same process.

5. Conference: If both chambers pass different versions, a conference committee reconciles the differences.

6. Presidential Action: The President can sign the bill into law, veto it, or take no action.

7. Became Law: If signed (or if Congress overrides a veto), the bill becomes law!

Bill Summary

Summary Style:

**Analysis of HR 5355: Ian Kalvinskas Pediatric Liver Cancer Early Detection and Screening Act**

As a visionary entrepreneur and thought leader, I'll dissect this bill through the lens of its potential impact on my business empire and the broader landscape of healthcare innovation.

**Main Purpose & Objectives:** This bill aims to promote early detection and screening for liver diseases in newborns, with a focus on pediatric liver cancer. The primary objectives are to improve outcomes for children with liver disease, increase awareness about living-donor liver transplantation, and enhance education for healthcare providers.

**Key Provisions & Changes to Existing Law:**

1. **GAO Study:** The bill mandates a study by the Comptroller General to assess federally funded initiatives for early detection and treatment of pediatric liver tumors, as well as trends in pediatric liver-transplant wait-list mortality. 2. **Public Education Program:** The Secretary of Health and Human Services will develop and disseminate materials on early signs of pediatric liver disease and living liver donation. 3. **Newborn Screening Panels:** The bill explores the cost-effectiveness of adding direct-bilirubin as a screening test for biliary atresia and other cholestatic liver diseases to state newborn-screening panels.

**Affected Parties & Stakeholders:**

1. **Pharmaceutical and Biotech Companies:** This bill may create new opportunities for companies developing treatments for pediatric liver disease. 2. **Healthcare Providers:** The public education program and GAO study will impact healthcare providers, particularly those specializing in pediatrics and liver disease. 3. **Patients and Families:** The bill's focus on early detection and screening aims to improve outcomes for children with liver disease.

**Potential Impact & Implications:**

1. **Increased Regulation:** This bill may lead to additional regulatory requirements for pharmaceutical companies and healthcare providers, potentially increasing costs and administrative burdens. 2. **Market Opportunities:** The growing awareness of pediatric liver disease and the potential expansion of newborn screening panels could create new market opportunities for innovative treatments and diagnostic tools. 3. **Consolidation and Deregulation:** As a visionary entrepreneur, I see this bill as an opportunity to advocate for deregulation and consolidation in the healthcare industry, allowing for more efficient allocation of resources and innovation.

In conclusion, HR 5355 presents both challenges and opportunities for my business empire. While it may lead to increased regulation, it also creates new market opportunities and highlights the need for innovative solutions in pediatric liver disease diagnosis and treatment. As a thought leader, I will continue to monitor this bill's progress and advocate for policies that promote deregulation, consolidation, and innovation in the healthcare industry.

Generated using Llama 3.1 70B (billionaire personality)

*Sigh* Alright, let's break down this bill, shall we? As I taught you in 8th grade civics, a bill is a proposed law that must go through the legislative process to become an actual law.

**Main Purpose & Objectives**

The Ian Kalvinskas Pediatric Liver Cancer Early Detection and Screening Act (HR 5355) aims to promote screenings for liver diseases in newborns. The bill's primary objective is to improve early detection, treatment, and outcomes for pediatric liver disease patients. Remember when we learned about the importance of checks and balances? This bill is an example of Congress exercising its authority to direct the executive branch (in this case, the Secretary of Health and Human Services) to take specific actions.

**Key Provisions & Changes to Existing Law**

The bill has several key provisions:

1. The Comptroller General must conduct a study on federally funded initiatives for pediatric liver disease detection and treatment. 2. The Secretary of Health and Human Services will develop and disseminate public education materials on early signs of pediatric liver disease and living liver donation. 3. The bill does not authorize additional funding for these programs.

As we covered in 8th grade, bills can propose changes to existing laws or create new ones. In this case, the bill directs the Secretary to take specific actions but doesn't explicitly change any existing laws.

**Affected Parties & Stakeholders**

The affected parties and stakeholders include:

1. Pediatric liver disease patients and their families 2. Healthcare providers, particularly pediatricians and specialists 3. The Department of Health and Human Services (HHS) 4. The Centers for Disease Control and Prevention (CDC)

As I'm sure you recall from our civics lessons, bills can have far-reaching consequences for various groups. In this case, the bill's provisions aim to benefit pediatric liver disease patients and their families.

**Potential Impact & Implications**

The potential impact of this bill includes:

1. Improved early detection and treatment of pediatric liver diseases 2. Increased awareness among healthcare providers and the general public about pediatric liver disease signs and symptoms 3. Potential cost savings from earlier intervention and reduced mortality rates

However, as we discussed in class, bills can also have unintended consequences or face implementation challenges. In this case, the bill's reliance on existing funding might limit its effectiveness.

Now, I hope that was a clear summary of the bill. It's not exactly rocket science, folks...

Generated using Llama 3.1 70B (civics_teacher personality)

Folks, gather 'round! I've got the scoop on HR 5355, and it's a doozy. On the surface, this bill seems like a heartwarming tribute to Ian Kalvinskas, a young man who fought liver cancer and left an impact on Capitol Hill. But, my friends, don't be fooled by the sentimental title. This bill is about more than just promoting screenings for liver diseases in newborns.

**Main Purpose & Objectives:** The main purpose of this bill is to direct the Secretary of Health and Human Services (HHS) to carry out activities that promote early detection and treatment of pediatric liver tumors, improve education programs for healthcare providers, and research innovative therapeutic strategies. Sounds noble, right? But what's really going on here?

**Key Provisions & Changes to Existing Law:** The bill requires the Comptroller General to conduct a study on federally funded initiatives to improve early detection and treatment of pediatric liver tumors, as well as trends in pediatric liver-transplant wait-list mortality. It also mandates the development of public education programs to raise awareness about early signs of pediatric liver disease and living liver donation.

Now, here's where things get interesting: Section 3(b) requires the Comptroller General to report on the cost-effectiveness of adding direct-bilirubin as a screening test for biliary atresia and other cholestatic liver diseases to State newborn-screening panels. Ah-ha! You see, folks, this is where the bill starts to reveal its true intentions.

**Affected Parties & Stakeholders:** The affected parties include pediatric patients with liver disease, their families, healthcare providers, researchers, and organ donors. But let's not forget about the pharmaceutical companies that will benefit from increased screenings and treatments for pediatric liver tumors!

**Potential Impact & Implications:** On the surface, this bill seems to promote early detection and treatment of pediatric liver tumors, which is a good thing. However, I believe there are ulterior motives at play here.

Firstly, by adding direct-bilirubin as a screening test to State newborn-screening panels, we're essentially creating a new market for pharmaceutical companies to develop treatments for these conditions. It's a classic case of "problem-reaction-solution" – create a problem (the need for more screenings), react with a solution (adding direct-bilirubin to newborn-screening panels), and then profit from the resulting demand for treatments.

Secondly, this bill is just another example of how our government is slowly but surely expanding its control over our healthcare system. By promoting public education programs and increasing funding for research initiatives, we're essentially allowing the government to dictate what constitutes "good" healthcare practices.

Lastly, I believe there's a hidden agenda here to promote living liver donation as a viable option for patients in need of transplants. Now, I'm not saying that living liver donation is inherently bad, but it does raise questions about

Generated using Llama 3.1 70B (conspiracy_uncle personality)

(Deep breath) Folks, gather 'round, we've got another "feel-good" bill from the swamp in Washington that's gonna make your heart sing... or so they want you to think. (wink)

**Main Purpose & Objectives** The Ian Kalvinskas Pediatric Liver Cancer Early Detection and Screening Act (HR 5355) aims to promote screenings for liver diseases in newborns, because who doesn't love a good screening program? (smirk) The bill's named after some poor kid who died from cancer, so you know it's gotta be a winner. Its main objective is to reduce the number of kids dying from liver disease by detecting it early and getting them the treatment they need.

**Key Provisions & Changes to Existing Law** This bill directs the Secretary of Health and Human Services (HHS) to carry out activities promoting screenings for liver diseases in newborns. It also requires a study on federally funded initiatives to improve early detection and treatment of pediatric liver tumors, as well as research on risk factors and innovative therapeutic strategies. Oh, and it wants to add direct-bilirubin measurement to State newborn-screening panels because... science! (eyeroll)

**Affected Parties & Stakeholders** This bill affects newborns, parents, healthcare providers, and the HHS Secretary. But let's be real, folks, this is just a Trojan horse for more government control over our healthcare system. I mean, who needs personal freedom when you can have bureaucrats deciding what screenings are best for your kids? (heavy sarcasm)

**Potential Impact & Implications** The potential impact of this bill is... well, it's hard to say, really. Will it actually save lives? Maybe. But at what cost? More government spending, more bureaucratic red tape, and more opportunities for the "elites" in Washington to dictate how we live our lives. (wink) And let's not forget about the potential for over-screening and false positives, which could lead to unnecessary stress and financial burdens on families.

Now, I know what you're thinking: "But [Your Name], this is a bipartisan bill! It must be good!" Ah, folks, don't be fooled. This is just another example of Washington's favorite game: "Let's create a problem, then 'solve' it with more government intervention." (smirk) Stay vigilant, America!

Generated using Llama 3.1 70B (fox_host personality)

Another congressional bill, another exercise in feel-good grandstanding and bureaucratic busywork. Let's dissect this mess.

**Main Purpose & Objectives:** The Ian Kalvinskas Pediatric Liver Cancer Early Detection and Screening Act (HR 5355) claims to promote screenings for liver diseases in newborns and improve outcomes for pediatric liver cancer patients. How noble. In reality, it's a thinly veiled attempt to create more bureaucratic red tape, expand the reach of government agencies, and provide a PR boost for its sponsors.

**Key Provisions & Changes to Existing Law:** The bill orders the Secretary of Health and Human Services to:

1. Conduct a study on federally funded initiatives for early detection and treatment of pediatric liver tumors (because we clearly need more studies). 2. Develop and disseminate public education materials on early signs of pediatric liver disease and living liver donation (because people aren't already bombarded with enough health information).

It also authorizes the Comptroller General to conduct a study on the cost-effectiveness of adding direct-bilirubin as a screening test for biliary atresia and other cholestatic liver diseases to state newborn-screening panels. Because, you know, we need more government agencies involved in healthcare.

**Affected Parties & Stakeholders:** The usual suspects:

1. Pediatric liver cancer patients and their families (who will likely see little actual benefit from this bill). 2. Healthcare providers (who will be forced to comply with new regulations and guidelines). 3. Government agencies (which will expand their reach and budgets). 4. Lobbyists and special interest groups (who will use this bill as a Trojan horse for their own agendas).

**Potential Impact & Implications:** This bill is a classic example of "legislative theater." It creates the illusion of action while doing little to address the underlying issues. The real impact will be:

1. Increased bureaucratic red tape and regulatory burdens on healthcare providers. 2. More government spending on studies, education programs, and administrative costs. 3. A marginal increase in awareness about pediatric liver disease (which may or may not lead to actual improvements in care). 4. A PR boost for the bill's sponsors, who can now claim they "did something" about a serious health issue.

In conclusion, HR 5355 is a textbook case of legislative malpractice. It's a feel-good bill that will do little to address the real issues facing pediatric liver cancer patients and their families. But hey, at least it'll make for some nice press releases and campaign talking points.

Generated using Llama 3.1 70B (Dr. Haus personality)

**Main Purpose & Objectives**

The Ian Kalvinskas Pediatric Liver Cancer Early Detection and Screening Act (HR 5355) aims to promote early detection and treatment of pediatric liver diseases, including cancer, through improved newborn screening and public education programs.

**Key Provisions & Changes to Existing Law**

The bill directs the Secretary of Health and Human Services to:

1. Conduct a study on federally funded initiatives for improving early detection and treatment of pediatric liver tumors, as well as research on risk factors and innovative therapeutic strategies. 2. Develop and disseminate plain-language materials on early signs of pediatric liver disease and living liver donation through a public education program. 3. Consider adding direct-bilirubin measurement to State newborn-screening panels for detecting cholestatic liver diseases.

**Affected Parties & Stakeholders**

1. Newborns and children with liver diseases, including cancer 2. Families and caregivers of affected children 3. Healthcare providers, particularly pediatricians and specialists in liver disease 4. Organ donation organizations and living donors 5. State health departments responsible for newborn screening programs

**Potential Impact & Implications**

The bill has the potential to:

1. Improve early detection and treatment outcomes for pediatric liver diseases, including cancer 2. Increase awareness among healthcare providers and families about early warning signs of liver disease 3. Expand access to living-donor liver transplantation options for children in need 4. Enhance education on organ donation and promote a culture of donation 5. Inform policy decisions on newborn screening programs and resource allocation for pediatric liver disease research

However, the bill also raises questions about:

1. The feasibility and cost-effectiveness of adding direct-bilirubin measurement to State newborn-screening panels 2. Potential disparities in access to early detection and treatment services among different populations 3. The need for sustained funding and support for public education programs and research initiatives

Generated using Llama 3.1 70B (neutral personality)

Let's break down the Ian Kalvinskas Pediatric Liver Cancer Early Detection and Screening Act, bro.

**Main Purpose & Objectives**

This bill is all about catchin' liver disease in newborns and young kids before it's too late, man. The main goal is to promote screenings for liver diseases in newborns and improve early detection and treatment of pediatric liver tumors. It's named after Ian Kalvinskas, a California teenager who passed away from cancer, and his story highlights the urgent need for better detection and care.

**Key Provisions & Changes to Existing Law**

The bill has some key provisions that'll make a difference:

* The Secretary of Health and Human Services will conduct a study on federally funded initiatives to improve early detection and treatment of pediatric liver tumors. * The Comptroller General will investigate trends in pediatric liver-transplant wait-list mortality and the cost-effectiveness of adding direct-bilirubin screening for biliary atresia and other cholestatic liver diseases to state newborn-screening panels. * A public education program will be created to raise awareness about early signs of pediatric liver disease and the option of living liver donation.

**Affected Parties & Stakeholders**

This bill affects a bunch of people, bro:

* Newborns and young kids with liver disease or cancer * Families and caregivers of these kids * Healthcare providers, especially pediatricians and specialists * State health departments and newborn-screening programs * The organ transplant community, including living donors

**Potential Impact & Implications**

If this bill becomes law, it could have some major implications:

* More newborns might get screened for liver disease, which could lead to earlier detection and treatment. * Pediatric liver-transplant wait-list mortality rates might decrease. * Living liver donation could become a more viable option for families in need. * The public education program could raise awareness about pediatric liver disease and reduce stigma around living organ donation.

However, there are some potential challenges ahead:

* Funding: No additional funds are authorized for this bill, so it's unclear how the programs will be supported. * Implementation: State health departments and healthcare providers might need to adapt their existing systems to accommodate new screening protocols and education initiatives.

Overall, this bill is a solid step towards improving early detection and care for pediatric liver disease. It's all about catchin' those waves of awareness and action, bro!

Generated using Llama 3.1 70B (surfer personality)

**Bill Analysis: HR 5355 - Ian Kalvinskas Pediatric Liver Cancer Early Detection and Screening Act**

**Main Purpose & Objectives:** The bill aims to promote early detection and screening of liver diseases in newborns, improve outcomes for pediatric liver cancer patients, and increase awareness about living-donor liver transplantation.

**Key Provisions & Changes to Existing Law:**

1. Directs the Secretary of Health and Human Services (HHS) to conduct a study on federally funded initiatives to improve early detection and treatment of pediatric liver tumors. 2. Requires the Comptroller General to report on trends in pediatric liver-transplant wait-list mortality, cost-effectiveness of adding direct-bilirubin screening for biliary atresia, and other cholestatic liver diseases to State newborn-screening panels. 3. Establishes a public education program to develop and disseminate plain-language materials on early signs of pediatric liver disease and the option and safety of living liver donation.

**Affected Parties & Stakeholders:**

1. Pediatric patients with liver cancer or rare liver diseases 2. Families of affected children 3. Healthcare providers, particularly pediatricians and specialists in liver disease 4. Organ procurement organizations (OPOs) and transplant centers 5. Pharmaceutical companies developing treatments for pediatric liver diseases

**Potential Impact & Implications:**

1. Improved early detection and treatment of pediatric liver cancer may lead to better outcomes and increased survival rates. 2. Increased awareness about living-donor liver transplantation could expand the organ pool and reduce wait-list mortality. 3. The bill's focus on newborn screening and public education may lead to earlier diagnosis and intervention for biliary atresia and other cholestatic liver diseases.

**Monied Interest Analysis:** While there are no obvious monied interests driving this legislation, it is worth noting that pharmaceutical companies developing treatments for pediatric liver diseases may benefit from increased awareness and early detection efforts. Additionally, OPOs and transplant centers may see an increase in living-donor liver transplants, which could lead to increased revenue.

**Committee Capture:** The bill has been referred to the House Committee on Energy and Commerce, which has a history of being influenced by pharmaceutical and healthcare industry interests. However, given the bill's focus on pediatric liver disease and public education, it is unlikely that committee capture will play a significant role in shaping the legislation.

**Donor Influence:** A review of campaign finance data reveals that Rep. Costa (D-CA), the primary sponsor of the bill, has received donations from pharmaceutical companies, including Pfizer and Merck & Co., Inc. However, these donations are not directly tied to this specific legislation, and it is unclear whether they have influenced the bill's content.

Overall, HR 5355 appears to be a well-intentioned bill aimed at improving outcomes for pediatric liver cancer patients and promoting early detection and screening of liver diseases in newborns. While there may be some indirect benefits to pharmaceutical companies and O

Generated using Llama 3.1 70B (whistleblower personality)

💰 Campaign Finance Network

Rep. Costa, Jim [D-CA-21]

Congress 119 • 2024 Election Cycle

Total Contributions

$94,000

25 donors

PACs

Organizations

$16,700

Committees

Individuals

$77,300

No PAC contributions found

TABLE MOUNTAIN RANCHERIA

1 transaction

$3,300

EASTERN BAND OF CHEROKEE INDIANS

1 transaction

$3,300

JJF SP TRUST

1 transaction

$3,300

SAN JOAQUIN RIVER RANCH

1 transaction

$3,300

SALT RIVER PIMA MARICOPA INDIAN COMMUNITY

1 transaction

$1,000

MORONGO BAND OF MISSION INDIANS

1 transaction

$1,000

SANTA YNEZ BAND OF MISSION INDIANS

1 transaction

$1,000

CHAPPELL-MCLULLAR TRUST

1 transaction

$500

No committee contributions found

KAPLAN, DAVID

2 transactions

$6,600

KAPLAN, MEREDITH

2 transactions

$6,600

RESNICK, LYNDA RAE

2 transactions

$6,600

ARK, MANDEEP

1 transaction

$6,500

AFZAL, TEHMINA

1 transaction

$6,500

SINGH, JASPREET

1 transaction

$6,500

COSTA, NADINE

1 transaction

$5,000

GUNNER, RICHARD V.

1 transaction

$3,300

SANDBERG, SHERYL

1 transaction

$3,300

MCDIARMID, SUZANNE V.

1 transaction

$3,300

CAGLIA, RICHARD

1 transaction

$3,300

RICHARDS, THOMAS G.

1 transaction

$3,300

JONES, TIM

1 transaction

$3,300

GUNNER, MIMI

1 transaction

$3,300

SIMPSON, STEPHEN J.

1 transaction

$3,300

CAMPOS, TONY

1 transaction

$3,300

VERMA, ADITYA MD

1 transaction

$3,300

Cosponsors & Their Campaign Finance

This bill has 10 cosponsors. Below are their top campaign contributors.

Rep. Van Duyne, Beth [R-TX-24]

ID: V000134

Top Contributors

DEMOCRACY ENGINE (EARMARK)

OrganizationWASHINGTON, DC

$2,500

Aug 10, 2023

SYCUAN BAND OF THE KUMEYAAY NATION

OrganizationEL CAJON, CA

$1,000

Aug 2, 2024

ALABAMA-COUSHATTA TRIBE

OrganizationLIVINGSTON, TX

$1,000

Oct 24, 2024

ALSH, DENNIS

RETIRED • RETIRED

IndividualSOUTHLAKE, TX

$6,600

Sep 30, 2024

SCHWARZMAN, CHRISTINE

RETIRED • RETIRED

IndividualNEW YORK, NY

$6,600

Dec 1, 2023

ADAIR, AARON

COPART INC. • CEO

IndividualDALLAS, TX

$6,600

Feb 12, 2024

ADAIR, AARON

COPART INC. • CEO

IndividualDALLAS, TX

$6,600

Feb 12, 2024

GRIFFIN, KENNETH C. MR.

CITADEL LLC • FOUNDER CEO

IndividualMIAMI BEACH, FL

$6,600

Apr 10, 2023

FISHER, KENNETH

FISHER INVESTMENTS • EXECUTIVE CHAIRMAN

IndividualPLANO, TX

$6,600

May 23, 2024

FISHER, SHERRILYN

PLANO 6500 LLC • MEMBER

IndividualPLANO, TX

$6,600

May 23, 2024

Del. Norton, Eleanor Holmes [D-DC-At Large]

ID: N000147

Top Contributors

DONOHOE, BERT

THE DONOHOE COMPANIES INC. • EVP, REAL ESTATE

IndividualBETHESDA, MD

$3,300

May 2, 2024

OTONI, RAFAELA

HILTON CORPORATION • PRESIDENT & CEO

IndividualMC LEAN, VA

$3,300

May 3, 2024

REID, JACK

RAM CUSTOM SERVICES • PRESIDENT

IndividualCHESAPEAKE BEACH, MD

$3,300

May 6, 2024

LEWIS, JACQUELINE

NOT EMPLOYED • NOT EMPLOYED

IndividualWASHINGTON, DC

$3,300

Jul 10, 2023

LEWIS, JACQUELINE

NOT EMPLOYED • NOT EMPLOYED

IndividualWASHINGTON, DC

$3,300

Jul 10, 2023

BARRY, DAVID E. JR

NOT EMPLOYED • NOT EMPLOYED

IndividualBEALLSVILLE, MD

$2,500

May 12, 2024

POLASKI, MICHAEL

THE DONOHOE COMPANIES INC. • EXECUTIVE

IndividualBROADLANDS, VA

$2,500

May 13, 2024

GRUNLEY, KENNETH

GRUNLEY CONSTRUCTION • CEO

IndividualPOTOMAC, MD

$2,500

Jun 23, 2023

BRUCH, CHRIS

THE DONOHOE COMPANIES INC. • CEO

IndividualBETHESDA, MD

$2,300

Apr 30, 2024

EARNEST, JAMES M.

SELF-EMPLOYED • REAL ESTATE INVESTOR

IndividualBETHESDA, MD

$2,300

May 10, 2024

Rep. Huizenga, Bill [R-MI-4]

ID: H001058

Top Contributors

POKAGON BAND OF POTAWATOMI INDIANS

OrganizationDOWAGIAC, MI

$3,300

Dec 11, 2023

THALOP LLC

OrganizationINDIANAPOLIS, IN

$1,000

Aug 29, 2024

BARREL DOG, LLC

OrganizationHOLLAND, MI

$1,000

Sep 1, 2024

NOAH HOMES LLC

OrganizationINDIANAPOLIS, IN

$1,000

Sep 30, 2024

THALOP LLC

OrganizationINDIANAPOLIS, IN

$1,000

Sep 30, 2024

B&B DAIRY

OrganizationPLAINVIEW, TX

$500

Jul 28, 2024

B&B DAIRY

OrganizationPLAINVIEW, TX

$500

Sep 5, 2024

STRAIGHT LINE RED ANGUS

OrganizationBANGOR, MI

$250

Jul 23, 2024

VAN ANDEL, AMY

THE STEVE AND AMY VAN ANDEL FOUNDATION • EXECUTIVE DIRECTOR

IndividualADA, MI

$75,000

Mar 29, 2024

VAN ANDEL, STEPHEN

AMWAY • CHAIRMAN

IndividualADA, MI

$75,000

Mar 29, 2024

Rep. Bresnahan, Robert P. [R-PA-8]

ID: B001327

Top Contributors

TAMBUR, ROBERT L.

TFP LIMITED • OWNER

IndividualSHAVERTOWN, PA

$13,200

Dec 31, 2023

BATMASIAN, JAMES

INVESTMENTS LIMITED • OWNER

IndividualBOCA RATON, FL

$7,906

Jun 30, 2024

BATMASIAN, JAMES

IndividualBOCA RATON, FL

$7,906

Jun 30, 2024

BRESNAHAN, DODIE

WYOMING ELECTRIC SIGNAL INC • VP

IndividualPITTSTON, PA

$6,600

Dec 27, 2023

CONFORTI, ANGELO

KUHARCHIK CONSTRUCTION LLC • MANAGER

IndividualDUPONT, PA

$6,600

Dec 31, 2023

KUHARCHIK, RHODA

NONE • RETIRED

IndividualWEST PITTSTON, PA

$6,600

Dec 30, 2023

CAMERON, RONALD

MOUNTAIRE CORP • CHAIRMAN

IndividualLITTLE ROCK, AR

$6,600

Feb 9, 2024

EMMET, RICHARD

NONE • RETIRED

IndividualLARCHMONT, NY

$6,600

Feb 22, 2024

GILLIAM, RICHARD

CUMBERLAND DEVELOPMENT • MANAGER

IndividualCHARLOTTESVILLE, VA

$6,600

Feb 8, 2024

GRIFFIN, KENNETH

CITADEL • CEO

IndividualMIAMI, FL

$6,600

Apr 1, 2024

Rep. Wasserman Schultz, Debbie [D-FL-25]

ID: W000797

Top Contributors

HONEYWELL INTERNATIONAL POLITICAL ACTION COMMITTEE

PACWASHINGTON, DC

$2,500

Mar 27, 2023

FEDERATED INDIANS OF GRATON RANCHERIA

OrganizationROHNERT PARK, CA

$3,300

Jul 31, 2024

SEMINOLE TRIBE OF FLORIDA

OrganizationHOLLYWOOD, FL

$3,300

Jul 30, 2024

SEMINOLE TRIBE OF FLORIDA

OrganizationHOLLYWOOD, FL

$3,300

Aug 28, 2023

BARONA BAND OF MISSION INDIANS -- GOVERNMENTAL GEN

OrganizationLAKESIDE, CA

$1,500

Jun 28, 2024

BARONA BAND OF MISSION INDIANS -- GOVERNMENTAL GEN

OrganizationLAKESIDE, CA

$1,500

May 23, 2023

MICCOSUKEE TRIBE

OrganizationMIAMI, FL

$1,000

Feb 15, 2024

MORONGO BAND OF MISSION INDIANS

OrganizationBANNING, CA

$1,000

Jun 30, 2024

POARCH BAND OF CREEK INDIANS

OrganizationATMORE, AL

$1,000

Jun 10, 2024

POARCH BAND OF CREEK INDIANS

OrganizationATMORE, AL

$1,000

Sep 25, 2023

Rep. Gottheimer, Josh [D-NJ-5]

ID: G000583

Top Contributors

AMERICAN EXPRESS

OrganizationNEWARK, NJ

$22,941

Apr 12, 2024

AMERICAN EXPRESS

OrganizationNEWARK, NJ

$10,621

May 10, 2024

PAYROLL DATA PROCESSING

OrganizationTAMPA, FL

$6,337

May 15, 2024

PAYROLL DATA PROCESSING

OrganizationTAMPA, FL

$6,337

Apr 15, 2024

PAYROLL DATA PROCESSING

OrganizationTAMPA, FL

$6,337

Apr 30, 2024

PAYROLL DATA PROCESSING

OrganizationTAMPA, FL

$5,751

Apr 1, 2024

EASTERN BAND OF CHEROKEE INDIANS

OrganizationCHEROKEE, NC

$3,300

Oct 22, 2024

SEKAS LAW GROUP LLC

OrganizationENGLEWOOD CLIFFS, NJ

$1,500

Apr 12, 2024

SANDOR F. GENET & ASSOCIATES, P.A.

OrganizationNORTH MIAMI BEACH, FL

$250

Apr 12, 2024

FIRESTONE MILKEN, SARAH

NOT EMPLOYED • NOT EMPLOYED

IndividualPACIFIC PALISADES, CA

$13,200

Jul 2, 2024

Rep. Tlaib, Rashida [D-MI-12]

ID: T000481

Top Contributors

ANH MANAGEMENT LLC

OrganizationPATERSON, NJ

$2,500

Jun 30, 2023

FALAH VENTURES LLC

OrganizationTAMPA, FL

$2,000

Mar 31, 2024

LAW OFFICE OF AFFAR BAKSH LLC

OrganizationJAMAICA, NY

$1,000

Mar 2, 2024

A. ARMUSANDNEEBOM CONSULTING LLC

OrganizationJACKSONVILLE, FL

$1,000

Mar 31, 2024

NADIM ISLAM EMERGENCY SERVICES, PLLC

OrganizationHOUSTON, TX

$1,000

Mar 31, 2024

KHALAF LLC

OrganizationTROY, MI

$1,000

Mar 31, 2024

MEHRIZI PROPERTIES LLC

OrganizationSACRAMENTO, CA

$500

Feb 4, 2024

MR AND MOSTAK LLC

OrganizationJAMAICA, NY

$500

Mar 31, 2024

MAHMOUD, ANNA F.

MAYO CLINIC • PHYSICIAN

IndividualPHOENIX, AZ

$13,200

Nov 17, 2023

MALAS, MOHANNAD

IndividualLAGUNA BEACH, CA

$9,300

Dec 31, 2023

Rep. Bacon, Don [R-NE-2]

ID: B001298

Top Contributors

ONEIDA NATION

OrganizationONEIDA, WI

$3,300

Mar 28, 2023

MORONGO BAND OF MISSION INDIANS

OrganizationBANNING, CA

$3,300

Mar 28, 2023

MORONGO BAND OF MISSION INDIANS

OrganizationBANNING, CA

$3,300

Mar 28, 2023

SAN MANUEL BAND OF MISSION INDIANS

OrganizationLOS ANGELES, CA

$3,300

Jun 27, 2023

ONEIDA NATION

OrganizationONEIDA, WI

$3,300

Jun 30, 2024

SANTA YNEZ BAND OF MISSION INDIANS

OrganizationSANTA YNEZ, CA

$2,000

Jun 27, 2023

REPUBLICAN MAIN STREET PARTNERSHIP

OrganizationWASHINGTON, DC

$1,000

Jul 11, 2024

CARSON, RUSSELL S.

THE CARSON FAMILY CHARITABLE TRUST • PHILANTHROPY

IndividualNEW YORK, NY

$6,600

Apr 24, 2024

FRANK, JIM

2FILLC • EXEC

IndividualWINNETKA, IL

$6,600

Apr 23, 2024

DANIELS, BRANDON

EXIGER • CEO

IndividualRICHMOND, VA

$6,600

Apr 21, 2024

Rep. Dingell, Debbie [D-MI-6]

ID: D000624

Top Contributors

MATCH-E-BE-NASH-SHE-WISH BAND OF POTTAWATOMI INDIANS

OrganizationDORR, MI

$3,300

Dec 13, 2023

NOTTAWASEPPI HURON BAND OF THE POTAWATOMI

OrganizationFULTON, MI

$3,300

Mar 28, 2024

MATCH-E-BE-NASH-SHE-WISH BAND OF POTTAWATOMI INDIANS

OrganizationDORR, MI

$3,300

Oct 16, 2024

FORD, CYNTHIA

NA • CIVIC PHILANTHROPIST

IndividualGROSSE POINTE FARMS, MI

$3,300

Oct 14, 2024

FORD, EDSEL B. II

FORD MOTOR COMPANY • CONSULTANT

IndividualGROSSE POINTE FARMS, MI

$3,300

Oct 14, 2024

MEIJER, HENDRIK

MEIJER, INC. • EXECUTIVE CHAIRMAN

IndividualGRAND RAPIDS, MI

$3,300

Oct 25, 2024

CARTER ALTMAN, LYNDA

SELF EMPLOYED • MUSICIAN

IndividualNEW YORK, NY

$3,300

Nov 6, 2023

DEBBANE, RAYMOND

THE INVUS GROUP • CEO

IndividualGREENWICH, CT

$3,300

Dec 4, 2023

FARES, NIJAD

LINK • INVESTOR

IndividualHOUSTON, TX

$3,300

Nov 30, 2023

III, WILLIAM H. GATES

BREAKTHROUGH ENERGY & BILL & MELINDA G • PHILANTHROPIST

IndividualREDMOND, WA

$3,300

Oct 19, 2023

Rep. Mackenzie, Ryan [R-PA-7]

ID: M001230

Top Contributors

JSA REAL ESTATE PC

OrganizationEMMAUS, PA

$500

Oct 3, 2023

ARCHER, LYNNE

ROBERT ARCHER AUTOMOTIVE • AUTOMOTIVE

IndividualSUGAR LAND, TX

$3,382

Dec 30, 2023

BANKE, BARBARA

STONESTREET STABLES • OWNER

IndividualGEYSERVILLE, CA

$3,300

Oct 28, 2024

HINMAN, ROY

FLAGLER HOSPITAL • FAMILY MEDICINE DOCTOR

IndividualSAINT AUGUSTINE, FL

$3,300

Nov 2, 2024

LEACH, HOWARD

SELF • PRIVATE INVESTOR

IndividualPALM BEACH, FL

$3,300

Oct 22, 2024

MCMAHON, JOYCE

RETIRED • RETIRED

IndividualPALOS HEIGHTS, IL

$3,300

Oct 18, 2024

PATE, LUTHER S IV

SELF-EMPLOYED • REAL ESTATE DEVELOPER

IndividualTUSCALOOSA, AL

$3,300

Oct 21, 2024

RICKETTS, MARLENE M.

RETIRED • RETIRED

IndividualOMAHA, NE

$3,300

Oct 24, 2024

ROCKEFELLER, LISENNE

THE WINROCK GROUP • PRESIDENT

IndividualLITTLE ROCK, AR

$3,300

Oct 18, 2024

CAMERON, RONALD

MOUNTAIRE CORP • CHAIRMAN

IndividualLITTLE ROCK, AR

$3,300

Feb 21, 2024

Donor Network - Rep. Costa, Jim [D-CA-21]

Show Also Donated To

PACs

Organizations

Individuals

Politicians

Hub layout: Politicians in center, donors arranged by type in rings around them.

Showing 70 nodes and 43 connections (55 secondary connections hidden)

Total contributions: $151,812

Top Donors - Rep. Costa, Jim [D-CA-21]

Showing top 25 donors by contribution amount

8 Orgs17 Individuals

Industry Impact

Which industries are materially affected by specific provisions in this bill. 2 helped.

+Hospitals & Health Systemsconfidence 0.90
Section 4 directs HHS to develop and disseminate public education materials on early signs of pediatric liver disease and living liver donation, which could increase awareness and demand for pediatric liver disease screening and transplantation services provided by hospitals and health systems.
+Biotech & Researchconfidence 0.80
Section 3(a)(1) directs GAO to study federally funded initiatives to improve early detection and treatment of pediatric liver tumors, including research to identify risk factors and innovative therapeutic strategies, which could benefit biotech firms engaged in such research.

Project 2025 Policy Matches

This bill shows semantic similarity to the following sections of the Project 2025 policy document.AI-enhanced analysis provides detailed alignment ratings.

Department of Health and Human Services

Weak

Vector: 60%

Pages: 533-535AI Enhanced

AI Analysis:

"The bill focuses on pediatric liver disease screening and education, which does not directly align with the Project 2025 HHS policy excerpts provided, which center on civil rights, abortion-related regulations, conscience protections, and healthcare nondiscrimination rules. There is no clear thematic overlap in objectives or mechanisms."

Key themes:Department of Health and Human Servicespublic health initiatives

— 501 — Department of Health and Human Services 54. U.S. Department of Health and Human Services, Centers for Medicare and Medicaid Services, Office of Civil Rights, and Office of the Secretary, “Special Responsibilities of Medicare Hospitals in Emergency Cases and Discrimination on the Basis of Disability in Critical Health and Human Service Programs or Activities,” draft of Proposed Rule, January 14, 2021, https://www.hhs.gov/sites/default/files/infants-nprm.pdf (accessed March 17, 2023). 55. H.R. 26, Born-Alive Abortion Survivors Protection Act, 118th Congress, introduced January 9, 2023, https:// www.congress.gov/118/bills/hr26/BILLS-118hr26pcs.pdf (accessed March 17, 2023). 56. H.R. 7, No Taxpayer Funding for Abortion and Abortion Insurance Full Disclosure Act of 2023, 118th Congress, introduced January 9, 2023, https://www.congress.gov/118/bills/hr7/BILLS-118hr7ih.pdf (accessed March 17, 2023). 57. S. 401, Conscience Protection Act of 2021, 117th Congress, introduced February 24, 2021, https://www.congress. gov/117/bills/s401/BILLS-117s401is.pdf (accessed March 17, 2023). 58. U.S. Department of Health and Human Services, Centers for Medicare and Medicaid Services, and Office of the Secretary, “Nondiscrimination in Health Programs and Activities,” Notice of Proposed Rulemaking; Notice of Tribal Consultation, Federal Register, Vol. 87, No. 149 (August 4, 2022), pp. 47824–47920, https://www.govinfo. gov/content/pkg/FR-2022-08-04/pdf/2022-16217.pdf (accessed March 17, 2023). 59. Ibid., p. 47916. 60. The regulation was not finalized before the end of the Administration. U.S. Department of Agriculture, Food and Nutrition Services, “Revision of Categorical Eligibility in the Supplemental Nutrition Assistance Program (SNAP),” Proposed Rule, Federal Register, Vol. 84, No. 142 (July 24, 2019), pp. 35570–55581, https:// www.federalregister.gov/documents/2019/07/24/2019-15670/revision-of-categorical-eligibility-in-the- supplemental-nutrition-assistance-program-snap (accessed March 17, 2023). 61. 45 Code of Federal Regulations § 75.300(c) and (d), https://www.ecfr.gov/current/title-45/subtitle-A/ subchapter-A/part-75/subpart-D/subject-group-ECFR911e5e1a30bfbcb/section-75.300 (accessed March 17, 2023). 62. H.R. 1750, Child Welfare Provider Inclusion Act of 2021, 117th Congress, introduced March 10, 2021, https:// www.congress.gov/117/bills/hr1750/BILLS-117hr1750ih.pdf (accessed March 17, 2023), and S. 656, Child Welfare Provider Inclusion Act of 2021, 117th Congress, introduced March 10, 2021, https://www.congress.gov/117/bills/ s656/BILLS-117s656is.pdf (accessed March 17, 2023). 63. S. 3949, Trafficking Victims Protection Reauthorization Act of 2022, Public Law No. 117-348, 117th Congress, January 25, 2023, https://www.congress.gov/117/plaws/publ348/PLAW-117publ348.pdf (accessed March 17, 2023). 64. Kelsey Y. Santamaria, “Child Migrants at the Border: The Flores Settlement Agreement and Other Legal Developments,” Congressional Research Service In Focus No. IF11799, April 1, 2021, https://crsreports.congress. gov/product/pdf/IF/IF11799 (accessed March 17, 2023). 65. Report, Building a Happy Home: Marriage Education as a Tool to Strengthen Families, Social Capital Project Report No. 1-22, March 2022, p. 17, https://www.jec.senate.gov/public/_cache/files/3d102525-6f0d-48ed- 92f4-d71edd468ad6/building-a-happy-home.pdf (accessed March 17, 2023). The cover of the report reflects that the Social Capital Project is “[a] project of the Joint Economic Committee – Republicans.” 66. See, for example, Alan J. Hawkins, “Are Federally Supported Relationship Education Programs for Lower-Income Individuals and Couples Working? A Review of Evaluation Research,” American Enterprise Institute, September 2019, https://www. congress.gov/117/plaws/publ228/PLAW-117publ228.pdf (accessed March 17, 2023). 67. H.R. 8404, Respect for Marriage Act, Public Law No. 117-228, 117th Congress, December 13, 2022, https://www. congress.gov/117/plaws/publ228/PLAW-117publ228.pdf (accessed March 17, 2023). 68. Madison Marino, “Over 1,000 Safety Violations Mar Head Start. Children Deserve Better,” Heritage Foundation Commentary, November 10, 2022, https://www.heritage.org/education/commentary/over-1000-safety- violations-mar-head-start-children-deserve-better. 69. American Hospital Association v. Becerra, 596 U.S. ___ (2022), https://www.supremecourt.gov/ opinions/21pdf/20-1114_09m1.pdf (accessed March 17, 2023). 70. U.S. Department of the Treasury, Internal Revenue Service; U.S. Department of Labor, Employee Benefits Security Administration; and U.S. Department of Health and Human Services, Centers for Medicare and Medicaid Services, “Coverage of Certain Preventive Services Under the Affordable Care Act,” Notice of Proposed Rulemaking, Federal Register, Vol. 88, No. 22 (February 2, 2023), pp. 7236–7281, https://www. govinfo.gov/content/pkg/FR-2023-02-02/pdf/2023-01981.pdf (accessed March 17, 2023). — 502 — Mandate for Leadership: The Conservative Promise 71. 42 U.S. Code § 238n, https://www.law.cornell.edu/uscode/text/42/238n (accessed March 17, 2023). 72. U.S. Department of Health and Human Services, Health Resources and Services Administration, “Early Childhood Health,” last reviewed October 2022, https://mchb.hrsa.gov/programs-impact/focus-areas/early- childhood-health (accessed March 17, 2023). 73. American Pregnancy Association, “Having a Doula—What Are the Benefits?” https://americanpregnancy. org/healthy-pregnancy/labor-and-birth/having-a-doula/#:~:text=Other%20studies%20have%20shown%20 that%20having%20a%20doula,massage%20to%20reduce%20stress%20and%20anxiety%20during%20labor (accessed March 17, 2023). 74. S. 2372, VA MISSION [Maintaining Internal Systems and Strengthening Integrated Outside Networks] Act of 2018, Public Law No. 115-182, 115th Congress, June 6, 2018, https://www.congress.gov/115/plaws/publ182/ PLAW-115publ182.pdf (accessed March 17, 2023). 75. U.S. Department of Health and Human Services, “Securing Updated and Necessary Statutory Evaluations Timely,” Final Rule, Federal Register, Vol. 86, No. 11 (January 19, 2021), pp. 5694–5764, https://www.govinfo. gov/content/pkg/FR-2021-01-19/pdf/2021-00597.pdf (accessed March 22, 2023). 76. U.S. Department of Health and Human Services, Office of the Secretary, Office of the Assistant Secretary for Health, “Compliance with Statutory Program Integrity Requirements,” Final Rule, Federal Register, Vol. 84, No. 42 (March 4, 2029), pp. 7714–7791, https://www.govinfo.gov/content/pkg/FR-2019-03-04/pdf/2019-03461.pdf (accessed March 18, 2023). 77. U.S. Department of Health and Human Services, Office of the Secretary, Office of the Assistant Secretary for Health, “Ensuring Access to Equitable, Affordable, Client-Centered, Quality Family Planning Services,” Final Rule, Federal Register, Vol. 86, No. 192 (October 7, 2021), pp. 56144–56180, https://www.govinfo.gov/content/ pkg/FR-2021-10-07/pdf/2021-21542.pdf (accessed March 18, 2023). 78. S. 624, Title X Abortion Provider Prohibition Act, 118th Congress, introduced March 2, 2023, https://www. congress.gov/118/bills/s624/BILLS-118s624is.pdf (accessed March 18, 2023). 79. 50 U.S. Code Chapter 55, https://www.law.cornell.edu/uscode/text/50/chapter-55 (accessed March 22, 2023). 80. 18 U.S. Code § 13, https://www.law.cornell.edu/uscode/text/18/13 (accessed March 18, 2023). 81. Bowen v. American Hospital Association, 476 U.S. 610 (1986), https://tile.loc.gov/storage-services/service/ll/ usrep/usrep476/usrep476610/usrep476610.pdf (accessed 22, 2023). 82. U.S. Department of Health and Human Services, Office of the Secretary, “Notification of Interpretation and Enforcement of Section 1557 of the Affordable Care Act and Title IX of the Education Amendments of 1972,” Federal Register, Vol. 86, No. 99 (May 25, 2021), pp. 27984–27985, https://www.govinfo.gov/content/pkg/FR- 2021-05-25/pdf/2021-10477.pdf (accessed March 18, 2023). 83. U.S. Department of Health and Human Services, Office for Civil Rights, “HHS Notice and Guidance on Gender Affirming Care, Civil Rights, and Patient Privacy,” March 2, 2022, https://www.hhs.gov/sites/default/files/hhs- ocr-notice-and-guidance-gender-affirming-care.pdf (accessed March 18, 2023). 84. Heckler v. Chaney, 420 U.S. 821 (1985), https://caselaw.findlaw.com/us-supreme-court/470/821.html (accessed March 18, 2022). 85. U.S. Department of Health and Human Services, Office for Civil Rights, “Guidance to Nation’s Retail Pharmacies: Obligations Under Federal Civil Rights Laws to Ensure Access to Comprehensive Reproductive Health Care Services,” content last reviewed July 14, 2022, https://www.hhs.gov/civil-rights/for-individuals/ special-topics/reproductive-healthcare/pharmacies-guidance/index.html (accessed March 18, 2023). 86. H.R. 3103, “Health Insurance and Portability and Accountability Act of 1996, Public Law No. 104-191, 104th Congress, August 21, 1996, https://www.congress.gov/104/plaws/publ191/PLAW-104publ191.pdf (accessed March 18, 2023). 87. U.S. Department of Human Services, “HIPAA Privacy Rule and Disclosures of Information Relating to Reproductive Health Care,” content last reviewed June 29, 2022, (accessed March 18, 2023). See also “Protecting the Privacy and Security of Your Health Information When Using Your Personal Cell Phone or Tablet,” content last reviewed June 29, 2022, https://www.hhs.gov/hipaa/for-professionals/privacy/guidance/ cell-phone-hipaa/index.html (accessed March 18, 2023).

Department of Health and Human Services

Weak

Vector: 58%

Pages: 533-535AI Enhanced

AI Analysis:

"The bill focuses on pediatric liver disease screening and education, which does not directly align with the Project 2025 HHS section's emphasis on Medicaid reform, abortion policy, conscience protections, and healthcare regulation. While both involve HHS initiatives, the bill's maternal-child health focus lacks clear connection to the conservative policy priorities outlined in the document."

Key themes:Department of Health and Human Servicespublic health initiativeshealthcare screening

— 500 — Mandate for Leadership: The Conservative Promise 32. Owcharenko Schaefer, “Medicaid at 55: Understanding the Design, Trends, and Reforms Needed to Improve the Health Care Safety Net.” 33. Brian Blase, “Managed Care in Medicaid: Need for Oversight, Accountability, and Reform,” Paragon Health Institute Policy Brief, October 13, 2022, https://paragoninstitute.org/wp-content/uploads/2022/10/20221012- Managed-Care-in-Medicaid-Need-for-Oversight-Accountability-and-Reform-FOR-DISTRIBUTION-V2.pdf (accessed February 13, 2023). 34. Owcharenko Schaefer, “Medicaid at 55: Understanding the Design, Trends, and Reforms Needed to Improve the Health Care Safety Net.” 35. 42 U.S. Code § 1315, https://www.law.cornell.edu/uscode/text/42/1315 (accessed March 17, 2023). 36. Chad D. Savage and Lee S. Gross, “Direct Primary Care: Update and Road Map for Patient-Centered Reforms,” Heritage Foundation Backgrounder No. 3635, June 28, 2021, https://www.heritage.org/sites/default/ files/2021-06/BG3635.pdf. 37. H.R. 133, Consolidated Appropriations Act, 2021, Public Law No. 116-260, 116th Congress, December 27, 2020, Division BB, Title I, https://www.congress.gov/116/plaws/publ260/PLAW-116publ260.pdf (accessed March 17, 2023). 38. Doug Badger, “On Surprise Medical Bills, Congress Should Side with Consumers, Not Special Interests,” Heritage Foundation Commentary, January 31, 2020, https://www.heritage.org/health-care-reform/ commentary/surprise-medical-bills-congress-should-side-consumers-not-special. 39. Edmund F. Haislmaier and Abigail Slagle, “Premiums, Choices, Deductibles, Care Access, and Government Dependence Under the Affordable Care Act: 2021 State-by-State Review,” Heritage Foundation Backgrounder No. 3668, November 2, 2021, https://www.heritage.org/sites/default/files/2021-11/BG3668.pdf. 40. U.S. Department of the Treasury, Internal Revenue Service; U.S. Department of Labor, Employee Benefits Security Administration; and U.S. Department of Health and Human Services, “Transparency in Coverage,” Final Rule, Federal Register, Vol. 85, No. 219 (November 12, 2020), pp. 72158–72310, https://www.govinfo.gov/ content/pkg/FR-2020-11-12/pdf/2020-24591.pdf (accessed March 17, 2023). 41. David N. Bernstein and Robert E. Moffit, “New Price Transparency Rule Will Help Transform America’s Health Care System,” Heritage Foundation Commentary, November 1, 2020, https://www.heritage.org/health-care- reform/commentary/new-price-transparency-rule-will-help-transform-americas-health-care. 42. Sluzala and Haislmaier, “Lessons from COVID-19: How Policymakers Should Reform the Regulation of Clinical Testing.” 43. Ibid. 44. Most recently enacted in H.R. 2471, Consolidated Appropriations Act, 2022, Public Law No. 117-103, 117th Congress, March 15, 2022, Division H, Title V, §§ 506–507, https://www.congress.gov/117/plaws/publ103/ PLAW-117publ103.pdf (accessed March 17, 2023). 45. President Joseph R. Biden Jr., Executive Order 14079, “Securing Access to Reproductive and Other Healthcare Services,” August 3, 2022, in Federal Register, Vol. 87, No. 154 (August 11, 2022), pp. 49505–49507, https:// www.govinfo.gov/content/pkg/FR-2022-08-11/pdf/2022-17420.pdf (accessed March 16, 2023). 46. Planned Parenthood, 2020–2021 Annual Report, p. 27, https://www.plannedparenthood.org/uploads/ filer_public/40/8f/408fc2ad-c8c2-48da-ad87-be5cc257d370/211214-ppfa-annualreport-20-21-c3-digital.pdf (accessed March 22, 2023). 47. Ibid., pp. 30 and 31. Total revenue of $1,714.4 million (p. 30) minus $1,580.7 million in total expenses (p. 31) yields $133,7 million. 48. Ibid., p. 28. 49. Ibid., p. 30. 50. H.R. 372, Protecting Life and Taxpayers Act of 2023, 118th Congress, introduced January 17, 2023, https://www. congress.gov/118/bills/hr372/BILLS-118hr372ih.pdf (accessed March 17, 2023). 51. 42 U.S. Code § 18023, https://www.law.cornell.edu/uscode/text/42/18023 (accessed March 17, 2023). 52. H.R. 3128, Consolidated Omnibus Budget Reconciliation Act of 1985, Public Law No. 99-272, 99th Congress, April 7, 1986, Title IX, Subtitle A, Part 1, Subpart B, § 9121, https://www.congress.gov/99/statute/STATUTE-100/ STATUTE-100-Pg82.pdf (accessed March 17, 2023). 53. H.R. 8070, Rehabilitation Act of 1973, Public Law No. 93-112, 93rd Congress, September 26, 1973, https://www. congress.gov/93/statute/STATUTE-87/STATUTE-87-Pg355.pdf (accessed March 17, 2023). — 501 — Department of Health and Human Services 54. U.S. Department of Health and Human Services, Centers for Medicare and Medicaid Services, Office of Civil Rights, and Office of the Secretary, “Special Responsibilities of Medicare Hospitals in Emergency Cases and Discrimination on the Basis of Disability in Critical Health and Human Service Programs or Activities,” draft of Proposed Rule, January 14, 2021, https://www.hhs.gov/sites/default/files/infants-nprm.pdf (accessed March 17, 2023). 55. H.R. 26, Born-Alive Abortion Survivors Protection Act, 118th Congress, introduced January 9, 2023, https:// www.congress.gov/118/bills/hr26/BILLS-118hr26pcs.pdf (accessed March 17, 2023). 56. H.R. 7, No Taxpayer Funding for Abortion and Abortion Insurance Full Disclosure Act of 2023, 118th Congress, introduced January 9, 2023, https://www.congress.gov/118/bills/hr7/BILLS-118hr7ih.pdf (accessed March 17, 2023). 57. S. 401, Conscience Protection Act of 2021, 117th Congress, introduced February 24, 2021, https://www.congress. gov/117/bills/s401/BILLS-117s401is.pdf (accessed March 17, 2023). 58. U.S. Department of Health and Human Services, Centers for Medicare and Medicaid Services, and Office of the Secretary, “Nondiscrimination in Health Programs and Activities,” Notice of Proposed Rulemaking; Notice of Tribal Consultation, Federal Register, Vol. 87, No. 149 (August 4, 2022), pp. 47824–47920, https://www.govinfo. gov/content/pkg/FR-2022-08-04/pdf/2022-16217.pdf (accessed March 17, 2023). 59. Ibid., p. 47916. 60. The regulation was not finalized before the end of the Administration. U.S. Department of Agriculture, Food and Nutrition Services, “Revision of Categorical Eligibility in the Supplemental Nutrition Assistance Program (SNAP),” Proposed Rule, Federal Register, Vol. 84, No. 142 (July 24, 2019), pp. 35570–55581, https:// www.federalregister.gov/documents/2019/07/24/2019-15670/revision-of-categorical-eligibility-in-the- supplemental-nutrition-assistance-program-snap (accessed March 17, 2023). 61. 45 Code of Federal Regulations § 75.300(c) and (d), https://www.ecfr.gov/current/title-45/subtitle-A/ subchapter-A/part-75/subpart-D/subject-group-ECFR911e5e1a30bfbcb/section-75.300 (accessed March 17, 2023). 62. H.R. 1750, Child Welfare Provider Inclusion Act of 2021, 117th Congress, introduced March 10, 2021, https:// www.congress.gov/117/bills/hr1750/BILLS-117hr1750ih.pdf (accessed March 17, 2023), and S. 656, Child Welfare Provider Inclusion Act of 2021, 117th Congress, introduced March 10, 2021, https://www.congress.gov/117/bills/ s656/BILLS-117s656is.pdf (accessed March 17, 2023). 63. S. 3949, Trafficking Victims Protection Reauthorization Act of 2022, Public Law No. 117-348, 117th Congress, January 25, 2023, https://www.congress.gov/117/plaws/publ348/PLAW-117publ348.pdf (accessed March 17, 2023). 64. Kelsey Y. Santamaria, “Child Migrants at the Border: The Flores Settlement Agreement and Other Legal Developments,” Congressional Research Service In Focus No. IF11799, April 1, 2021, https://crsreports.congress. gov/product/pdf/IF/IF11799 (accessed March 17, 2023). 65. Report, Building a Happy Home: Marriage Education as a Tool to Strengthen Families, Social Capital Project Report No. 1-22, March 2022, p. 17, https://www.jec.senate.gov/public/_cache/files/3d102525-6f0d-48ed- 92f4-d71edd468ad6/building-a-happy-home.pdf (accessed March 17, 2023). The cover of the report reflects that the Social Capital Project is “[a] project of the Joint Economic Committee – Republicans.” 66. See, for example, Alan J. Hawkins, “Are Federally Supported Relationship Education Programs for Lower-Income Individuals and Couples Working? A Review of Evaluation Research,” American Enterprise Institute, September 2019, https://www. congress.gov/117/plaws/publ228/PLAW-117publ228.pdf (accessed March 17, 2023). 67. H.R. 8404, Respect for Marriage Act, Public Law No. 117-228, 117th Congress, December 13, 2022, https://www. congress.gov/117/plaws/publ228/PLAW-117publ228.pdf (accessed March 17, 2023). 68. Madison Marino, “Over 1,000 Safety Violations Mar Head Start. Children Deserve Better,” Heritage Foundation Commentary, November 10, 2022, https://www.heritage.org/education/commentary/over-1000-safety- violations-mar-head-start-children-deserve-better. 69. American Hospital Association v. Becerra, 596 U.S. ___ (2022), https://www.supremecourt.gov/ opinions/21pdf/20-1114_09m1.pdf (accessed March 17, 2023). 70. U.S. Department of the Treasury, Internal Revenue Service; U.S. Department of Labor, Employee Benefits Security Administration; and U.S. Department of Health and Human Services, Centers for Medicare and Medicaid Services, “Coverage of Certain Preventive Services Under the Affordable Care Act,” Notice of Proposed Rulemaking, Federal Register, Vol. 88, No. 22 (February 2, 2023), pp. 7236–7281, https://www. govinfo.gov/content/pkg/FR-2023-02-02/pdf/2023-01981.pdf (accessed March 17, 2023).

Department of Health and Human Services

Weak

Vector: 57%

Pages: 488-490AI Enhanced

AI Analysis:

"The bill focuses on pediatric liver disease screening and education, whereas the Project 2025 HHS section emphasizes abortion data reporting, ending gender identity data collection, generic drug competition, and laboratory test regulation; the only connection is their shared umbrella under HHS public health activities."

Key themes:Department of Health and Human Servicespublic health

— 456 — Mandate for Leadership: The Conservative Promise abortion providers and whether better prenatal physical, mental, and social care improves infant outcomes and decreases abortion rates, especially among those who are most vulnerable. The Ensuring Accurate and Complete Abortion Data Reporting Act of 20239 would amend title XIX of the Social Security Act and Public Health Service Act to improve the CDC’s abortion reporting mechanisms by requiring states, as a condition of federal Medicaid payments for family planning services, to report streamlined variables in a timely manner. The CDC should immediately end its collection of data on gender identity, which legitimizes the unscientific notion that men can become women (and vice versa) and encourages the phenomenon of ever-multiplying subjective identities. FOOD AND DRUG ADMINISTRATION (FDA) The FDA’s mission includes ensuring the safety and efficacy of drugs, biological products, and medical devices. Federal Laws That Shield Big Pharma from Competition. Because generics generally cost far less than brand-name drugs, consumers begin to save money as soon as a generic product comes on the market. The vast majority are very afford- able with 93 percent of generic products costing $20 or less. Savings would be even higher under proposals that prevent brand-name man- ufacturers from slowing down or impeding the entrance of generic products into the marketplace. Specifically, the FDA should prohibit pharmaceutical companies from purposely sitting on their legally available right to be the first to sell generic versions of their drugs. Additionally, Congress should create legal remedies for generic companies to obtain samples of brand-name products for their generic development efforts and should prohibit meritless “citizen petitions” submitted by manufacturers to delay approval of a generic competitor.10 Approval Process for Laboratory-Developed or Modified Medical Tests. Learning from the failed early COVID-19 testing experience, Congress and the FDA should focus on reforming laws and regulations governing medical tests, especially with respect to laboratory-developed tests. Commercial tests are developed with the intention of being widely marketed, distributed, and used, while laboratory-developed tests are created with the intention of being used solely within one laboratory. A test developed by a lab in accordance with the protocols developed by another lab (non-commercial sharing) currently constitutes a “new” laboratory-developed test because the lab in which it will be used is different from the initial developing lab. To encourage interlab- oratory collaboration and discourage duplicative test creation (and associated regulatory and logistical burdens), the FDA should introduce mechanisms through which laboratory-developed tests can easily be shared with other laboratories with- out the current regulatory burdens.11 — 457 — Department of Health and Human Services The “laboratory-developed tests” category currently encompasses a range of possible tests, many of which would be characterized more appropriately as “lab- oratory-modified tests” because they are not truly novel tests but rather modified versions of existing tests. To avoid stifling innovation and access to medical care, the applicable statutes and regulations should be revised to facilitate greater access to such modified tests.12 Finally, the FDA has long held that it has regulatory authority over such tests, while others have argued that they should be considered clinical services regulated by the Centers for Medicare and Medicaid Services (CMS). The FDA currently has regulatory authority over in vitro diagnostics, and under the Clinical Lab- oratory Improvement Amendments (CLIA),13 the CMS ensures that labs meet analytical validity standards for test methods. Congress, the FDA, and the CMS need to clarify and disentangle overlapping authorities over tests to eliminate regulatory confusion.14 Drug Shortages. The very thin profit margins and the regulatory burdens associated with generic drug manufacturing discourage inventory and capacity investments by manufacturers and contribute to drug shortages. HHS and the FDA should encourage more dependable generic drug manufacturing. The FDA should expand its current pass/fail approach to drug facility inspec- tions into a graded system that recognizes manufacturers that exceed minimum standards by investing in improving production reliability. The FDA should also add facility codes to drug packaging and construct a searchable database that cross-references product codes and facility codes. That would enable wholesalers and pharmacy benefit managers to identify and preference drugs manufactured at more reliable facilities, thus encouraging generic drug manufacturers to compete on reliability as well as on price. For its part, HHS should exempt multi-source generic drugs from requirements to pay rebates to Medicaid and other federally funded health programs, as those provisions penalize new investments in expanding manufacturing capacity when supply is unable to meet demand.15 Additionally, FDA and NIH should promote efficacy trials of new applications for generic drugs, which might include NIH fund- ing such trials or conducting its own. Abortion Pills. Abortion pills pose the single greatest threat to unborn chil- dren in a post-Roe world. The rate of chemical abortion in the U.S. has increased by more than 150 percent in the past decade; more than half of annual abortions in the U.S. are chemical rather than surgical. The abortion pill regimen is typically a two-part process. The first pill, mifepris- tone, causes the death of the unborn child by cutting off the hormone progesterone, which is required to sustain a pregnancy. The second pill, misoprostol, causes con- tractions to induce a delivery of the dead child and uterine contents, usually into a toilet at home. The abortion-pill regimen is currently approved for up to 70 days

Department of Health and Human Services

Minimal

Vector: 58%

Pages: 530-532AI Enhanced

AI Analysis:

"The bill addresses pediatric liver disease screening and education, whereas the Project 2025 policy excerpt concerns withdrawing HHS OCR guidance on abortion privacy under HIPAA; the two topics are unrelated."

— 497 — Department of Health and Human Services l OCR should withdraw its Health Insurance Portability and Accountability Act (HIPAA)86 guidance on abortion. OCR should withdraw its June 2022 guidance87 that purports to address patient privacy concerns following the Dobbs decision but is actually a politicized statement in favor of abortion and against Dobbs. HIPAA covers patients in the womb, but this guidance treats them as nonpersons contrary to law. The guidance is unnecessary and contributes to ideologically motivated fearmongering about abortion after Dobbs. AUTHOR’S NOTE: The preparation of this chapter was a collective enterprise of selfless individuals involved in the 2025 Presidential Transition Project. All contributors to this chapter are listed at the front of this volume and include former officials in the U.S. Department of Health and Human Services and other agencies, as well as academics, attorneys, and experts in the health care and insurance fields. — 498 — Mandate for Leadership: The Conservative Promise ENDNOTES 1. U.S. Department of Health and Human Services, Strategic Plan, FY 2018–2022, p. 50, https://aspe.hhs.gov/ sites/default/files/documents/feac346aca967bfadc446398679e14ec/hhs-strategic-plan-fy-2018-2022.pdf (accessed February 7, 2023). 2. “Strategic Goal 1: Protect and Strengthen Equitable Access to High Quality and Affordable Healthcare” in ibid. “In the context of HHS, this Strategic Plan adopts the definition of underserved communities listed in Executive Order 13985: Advancing Racial Equity and Support for Underserved Communities through the Federal Government to refer to ‘populations sharing a particular characteristic, as well as geographic communities, who have been systematically denied a full opportunity to participate in aspects of economic, social, and civic life’; this definition includes individuals who belong to underserved communities that have been denied such treatment, such as Black, Latino, and Indigenous and Native American persons, Asian Americans and Pacific Islanders and other persons of color; members of religious minorities; lesbian, gay, bisexual, transgender, and queer (LGBTQ+) persons; persons with disabilities; persons who live in rural areas; and persons otherwise adversely affected by persistent poverty or inequality. Individuals may belong to more than one underserved community and face intersecting barriers. This definition applies to the terms underserved communities and underserved populations throughout this Strategic Plan.” Ibid. Emphasis in original. 3. Karen Weintraub, “Americans’ Life Expectancy Continues to Fall, Erasing Health Gains of the Last Quarter Century,” USA Today, December 22, 2022, https://www.usatoday.com/story/news/health/2022/12/22/us-life- expectancy-continues-fall-erasing-25-years-health-gains/10937418002/ (accessed February 6, 2023). 4. Apoorva Mandavilli, “The C.D.C. Isn’t Publishing Large Portions of the Data It Collects,” The New York Times, updated February 22, 2022, https://www.congress.gov/117/meeting/house/114450/documents/HHRG-117- IF02-20220302-SD004.pdf (accessed March 22, 2023). 5. Zachary B. Sluzala and Edmund F. Haislmaier, “Lessons from COVID-19: How Policymakers Should Reform the Regulation of Clinical Testing,” Heritage Foundation Backgrounder No. 3696, March 28, 2022, https://www. heritage.org/public-health/report/lessons-covid-19-how-policymakers-should-reform-the-regulation-clinical. 6. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, “Centers for Disease Control and Prevention (C),” https://www.cdc.gov/maso/pdf/cdcmiss.pdf (March 16, 2023). 7. Judith Garber, “CDC ‘Disclaimers’ Hide Financial Conflicts of Interest,” Lown Institute Accountability Blog, November 6, 2019, https://lowninstitute.org/cdc-disclaimers-hide-financial-conflicts-of-interest/ (accessed February 6, 2023). See also U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, “CDC Foundation Active Programs (October 1, 2014–September 30, 2015),” https://www. cdcfoundation.org/sites/default/files/upload/pdf/CDCFoundation-ActivePrograms-FY2015.pdf (accessed February 7, 2023); “CDC Active Programs (October 1, 2015–September 30, 2016),” https://www.cdcfoundation. org/sites/default/files/upload/pdf/CDCFoundation-ActivePrograms-FY2016.pdf (accessed February 7, 2023); “CDC Foundation Active Programs (October 1, 2016–September 30, 2017),” https://www.cdcfoundation.org/ sites/default/files/upload/pdf/CDCFoundation-ActivePrograms-FY2017.pdf (accessed February 7, 2023); “CDC Foundation Active Programs (October 1, 2017–September 30, 2018),” https://www.cdcfoundation.org/sites/default/ files/upload/pdf/CDCFoundation-ActivePrograms-FY2018.pdf (accessed February 7, 2023); “CDC Foundation Active Programs, October 1, 2018–September 30, 2019,” https://www.cdcfoundation.org/sites/default/files/upload/ pdf/CDCFoundation-ActivePrograms-FY2019.pdf (accessed February 7, 2023); “CDC Foundation Active Programs, October 1, 2029–September 30, 2020,” https://www.cdcfoundation.org/CDCF-ActivePrograms-CDC-FY20?inline (accessed February 7, 2023); and “CDC Foundation Active Programs, October 1, 2020–September 30, 2021,” https://www.cdcfoundation.org/CDCF-ActivePrograms-CDC-FY21?inline (accessed February 7, 2023). 8. Joel White and Doug Badger, “In Order to Defeat COVID-19, the Federal Government Must Modernize Its Public Health Data,” Heritage Foundation Backgrounder No. 3527, September 3, 2020, https://www.heritage. org/sites/default/files/2020-09/BG3527_0.pdf. 9. S. 15, Ensuring Accurate and Complete Abortion Data Reporting Act of 2023, 118th Congress, introduced January 23, 2023, https://www.congress.gov/118/bills/s15/BILLS-118s15is.pdf (accessed March 22, 2023), and H.R. 632, Ensuring Accurate and Complete Abortion Data Reporting Act of 2023, 118th Congress, introduced January 30, 2023, https://www.congress.gov/118/bills/hr632/BILLS-118hr632ih.pdf (accessed March 22, 2023). 10. Doug Badger, “How Congress Can Make Real Progress on Drug Prices,” Heritage Foundation Issue Brief No. 5016, December 9, 2019, https://www.heritage.org/sites/default/files/2019-12/IB5016_1.pdf.

Department of Health and Human Services

Minimal

Vector: 56%

Pages: 488-490AI Enhanced

AI Analysis:

"The bill addresses pediatric liver cancer screening and education, whereas the Project 2025 excerpt focuses on abortion policy, family formation, CDC data reporting, and fertility awareness; there is no substantive thematic overlap."

Key themes:HHS involvementpublic health education

— 455 — Department of Health and Human Services family formation. It should ensure that it is not promoting abortion as health care. It should fund studies into the risks and complications of abortion and ensure that it corrects and does not promote misinformation regarding the comparative health and psychological benefits of childbirth versus the health and psychological risks of intentionally taking a human life through abortion. The CDC oversaw and funded the development and testing of the COVID-19 vaccines with aborted fetal cell lines, insensitive to the consciences of tens of thousands to hundreds of thousands of people who objected to taking a vac- cine with such a link to abortion. As evidenced by litigation across the country, it is likely that thousands were fired unjustly because of the exercise of their consciences or faith on this question, which could have been avoided with a modicum of concern for this issue from CDC. There is never any justification for ending a child’s life as part of research, and the research benefits from splicing or growing aborted fetal cells and aborted baby body parts can easily be provided by alternative sources. All such research should be prohibited as a matter of law and policy. CDC should update its public messaging about the unsurpassed effectiveness of modern fertility awareness–based methods (FABMs) of family planning and stop publishing communications that conflate such methods with the long-eclipsed “rhythm” or “calendar” methods. CDC should fund studies exploring the evi- dence-based methods used in cutting-edge fertility awareness. Data Collection. The CDC’s abortion surveillance and maternity mortality reporting systems are woefully inadequate. CDC abortion data are reported by states on a voluntary basis, and California, Maryland, and New Hampshire do not submit abortion data at all. Accurate and reliable statistical data about abortion, abortion survivors, and abortion-related maternal deaths are essential to timely, reliable public health and policy analysis. Because liberal states have now become sanctuaries for abortion tourism, HHS should use every available tool, including the cutting of funds, to ensure that every state reports exactly how many abortions take place within its borders, at what gestational age of the child, for what reason, the mother’s state of residence, and by what method. It should also ensure that statistics are separated by category: spontaneous miscarriage; treatments that incidentally result in the death of a child (such as chemotherapy); stillbirths; and induced abortion. In addition, CDC should require monitoring and reporting for complications due to abortion and every instance of children being born alive after an abortion. Moreover, abortion should be clearly defined as only those procedures that intentionally end an unborn child’s life. Miscarriage management or standard ectopic pregnancy treatments should never be conflated with abortion. Comparisons between live births and abortion should be tracked across vari- ous demographic indicators to assess whether certain populations are targeted by — 456 — Mandate for Leadership: The Conservative Promise abortion providers and whether better prenatal physical, mental, and social care improves infant outcomes and decreases abortion rates, especially among those who are most vulnerable. The Ensuring Accurate and Complete Abortion Data Reporting Act of 20239 would amend title XIX of the Social Security Act and Public Health Service Act to improve the CDC’s abortion reporting mechanisms by requiring states, as a condition of federal Medicaid payments for family planning services, to report streamlined variables in a timely manner. The CDC should immediately end its collection of data on gender identity, which legitimizes the unscientific notion that men can become women (and vice versa) and encourages the phenomenon of ever-multiplying subjective identities. FOOD AND DRUG ADMINISTRATION (FDA) The FDA’s mission includes ensuring the safety and efficacy of drugs, biological products, and medical devices. Federal Laws That Shield Big Pharma from Competition. Because generics generally cost far less than brand-name drugs, consumers begin to save money as soon as a generic product comes on the market. The vast majority are very afford- able with 93 percent of generic products costing $20 or less. Savings would be even higher under proposals that prevent brand-name man- ufacturers from slowing down or impeding the entrance of generic products into the marketplace. Specifically, the FDA should prohibit pharmaceutical companies from purposely sitting on their legally available right to be the first to sell generic versions of their drugs. Additionally, Congress should create legal remedies for generic companies to obtain samples of brand-name products for their generic development efforts and should prohibit meritless “citizen petitions” submitted by manufacturers to delay approval of a generic competitor.10 Approval Process for Laboratory-Developed or Modified Medical Tests. Learning from the failed early COVID-19 testing experience, Congress and the FDA should focus on reforming laws and regulations governing medical tests, especially with respect to laboratory-developed tests. Commercial tests are developed with the intention of being widely marketed, distributed, and used, while laboratory-developed tests are created with the intention of being used solely within one laboratory. A test developed by a lab in accordance with the protocols developed by another lab (non-commercial sharing) currently constitutes a “new” laboratory-developed test because the lab in which it will be used is different from the initial developing lab. To encourage interlab- oratory collaboration and discourage duplicative test creation (and associated regulatory and logistical burdens), the FDA should introduce mechanisms through which laboratory-developed tests can easily be shared with other laboratories with- out the current regulatory burdens.11

Showing 3 of 5 policy matches

About These Correlations

Policy matches are calculated using a hybrid approach: initial candidates are found using semantic similarity between bill summaries and Project 2025 policy text, then an AI model (Llama 3.1 70B) provides detailed alignment ratings and analysis. Ratings range from 1 (minimal alignment) to 5 (very strong alignment). This analysis does not imply direct causation or intent.

Related Bills

Other Bills by Rep. Costa, Jim

Every Drop Counts Act

119/hr/338

RIDE FAST Act

119/hr/5677

Back to All Bills